.Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX16_Piflufolastat18f.Piflufolastat18f .Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX16_Piflufolastat18f.Piflufolastat18f| name: | Piflufolastat18f | |
| ATC code: | V09IX16 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 370 | mg |
| volume of distribution: | 0.22 | L |
| clearance: | 1.5 | L/h |
| other parameters in model implementation | ||
Piflufolastat (18F), also known as 18F-DCFPyL, is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. It is FDA-approved for use in prostate cancer patients with suspected metastasis or recurrence.
Pharmacokinetic parameters estimated from published clinical characteristics, predominantly in adult male prostate cancer patients, after intravenous administration.